miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma

Figure 4 Kaplan-Meier overall and disease-free survival curve of patients with hepatitis B virus-associated hepatocellular carcinoma based on miR-106b expression (n = 108). Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) patients were divided into two groups including miR-106b low (n = 20) and miR-106b high (n = 88) groups based on the expression levels of miR-106b. A: Overall survival curve; B: Disease-free survival curve. Log-rank test was used for statistical analysis. P < 0.05 was considered significant.